Home・Stock List・AbCellera Biologics Inc

AbCellera Biologics Inc

Closed

SectorHealthcare

6.93 6.13

Buy Sell

Overview

Share price change

24h

Current

Min

6.65

Max

6.98

Key metrics
By Trading Economics
Income	-34M -43M
Sales	-37M 8.3M
EPS	-0.14
Profit margin	-519.122
Employees	562
EBITDA	-23M -41M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+56.28% upside

Dividends
By Acuity
Next Earnings	5 Nov 2026

Market Stats
By TradingEconomics
Market Cap	178M 1.8B
Previous open	0.8
Previous close	6.93

News Sentiment

By Acuity

47%

53%

119 / 340 Healthcare

AbCellera Biologics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 Aug 2026, 00:06 UTC

Event

News

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

7 Aug 2026, 23:21 UTC

Social Media

News

Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

6 Aug 2026, 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

5 Aug 2026, 23:02 UTC

Social Media

News

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

3 Aug 2026, 19:36 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

31 Jul 2026, 19:33 UTC

Correlated Moves

Social Media

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

30 Jul 2026, 23:41 UTC

Correlated Moves

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

29 Jul 2026, 23:51 UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

28 Jul 2026, 19:41 UTC

News

Abcellera Biologics is rising, driven by gains in the Life Sciences Tools & Services sector and positive trends in the antibody therapeutics market.

27 Jul 2026, 19:46 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher, reflecting a modest increase since Friday's close. Broader market gains may influence sentiment in life sciences.

24 Jul 2026, 23:46 UTC

Abcellera Biologics Inc shares are higher in after-market hours, showing resilience despite recent challenges in the bond market and declining prices.

22 Jul 2026, 20:06 UTC

Abcellera Biologics Inc shares are lower today, reflecting broader market trends amid uncertainty ahead of the Federal Reserve meeting on July 29.

21 Jul 2026, 23:06 UTC

Correlated Moves

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

20 Jul 2026, 23:16 UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.

Peer Comparison

Price change

AbCellera Biologics Inc Forecast

Price Target

By TipRanks

56.28% upside

12 Months Forecast

Average 10.83 USD 56.28%

High 13 USD

Low 7 USD

Based on 7 Wall Street analysts offering 12 month price targets forAbCellera Biologics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to AbCellera Biologics Inc - Dist in the past 3 months.

Sentiment

By Acuity

119 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.